At the news
? BULLISHIMPACT 6/10 425 filed Sep 30, 2026 at 17:28 ET
Standard BioTools terminated its prior agreement to sell its mass cytometry business to Multiplex Bio and entered into a new $5.5 million cash deal with Element Biosystems (GMT Venture), which the board deemed a superior proposal. The new deal eliminates a $10 million working capital loan obligation, improving net cash by ~$15 million for the pending Treeline merger. The transaction requires stockholder approval and is expected to close by end of 2026 concurrently with the Treeline merger.
- Standard BioTools terminated the Multiplex Bio purchase agreement and entered a new agreement with Element Biosystems (GMT Venture) for $5.5 million cash.
- The new deal eliminates a $10 million working capital loan that was required under the Multiplex Bio agreement.
- Net cash position for the Treeline merger exchange ratio calculation improves by approximately $15 million versus the Multiplex Bio deal.
- GMT Venture paid $1.0 million of the $1.5 million Multiplex Bio termination fee on Standard BioTools' behalf.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access